Skip to main content

Table 1 Clinical cohort description

From: Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer

A. Hamburg cohort

B. ProCOC cohort

PSA Density

Gleason

NCCN

Patients

PSA Density

Gleason

NCCN

Patients

< 0.14

≤ 7

1

36

< 0.14

≤ 7

1

47

0.03–0.31

6–7

2

13

0.01–0.31

6–7

2

30

0.02–0.88

6–8

3

55

0.02–0.53

6–9

3

146

0.04–0.98

6–9

4

13

0.03–0.93

7–9

4

40

0.04

6

NA

1

TOTAL

263

TOTAL

118

    
  1. A. Summary of clinical parameters of Hamburg (HH) prostatectomy cohort with clinical PSA follow-up of a median of 25 months. B. Summary of clinical parameters of the ProCOC cohort with clinical PSA follow-up of a median of 34 months